Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs EOLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EOLS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

EOLS Overall Winner 6-Pillar Tally: TLPH 1 – 5 EOLS Matrix Metrics: TLPH 5 – 5 EOLS

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas EOLS carries 47.8/100 (HOLD) at $6.69 (24.9x Forward P/E, -5.4% operating margin).

  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs EOLS
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
EOLS NASDAQ Head-to-Head Winner
Evolus, Inc. Common Stock
Pharmaceutical Preparations
$6.69
-3.88% 1D
Market Cap $475.2M
TTM Revenue $325M
Forward P/E 24.9x
Beta / 30D Vol 1.31β · 60% Vol
Unified Composite Score
47.8 / 100 HOLD
Tech 51.0 Fund 53.0 Flow 72.0 Mom 39.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $7.20 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 5 EOLS)

Columns: Metric · TLPH · EOLS
1. Valuation Multiples TLPH
Forward P/E 1.0x 24.9x
Trailing P/E 1.0x 14.9x
PEG Ratio N/M N/M
EV / Revenue N/M 1.8x
2. Growth & Scale EOLS
Revenue Growth (YoY) +0.0% +13.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $325M
Market Cap $53.7M $475.2M
3. Profitability & Quality EOLS
Gross Margin N/A 66.1%
Operating Margin -1474700.0% -5.4%
Net Profit Margin 0.0% -9.6%
Return on Equity (ROE) -143.4% -18729.6%
4. Balance Sheet & Cash Flow EOLS
Cash Generation (TTM) -$15M EBITDA -$8.8M
Cash Flow Margin N/A -2.7%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $124M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EOLS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 118.4% (100th %ile) 46.4% (4th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat EOLS
OpEx & R&D Intensity N/A 71.5% of Rev ($233M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (5) vs EOLS (5)
Institutional Metric TLPH EOLS Criterion Row Edge
Market Capitalization
Scale
$53.7M $475.2M Larger Scale EOLS
Trailing P/E Ratio
Valuation
1.0x 14.9x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 24.9x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +13.0% Higher Growth EOLS
Operating Margin (TTM)
Profitability
-1474700.0% -5.4% Higher Margin EOLS
Net Profit Margin
Profitability
0.0% -9.6% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% -18729.6% Higher ROE TLPH
52-Week Range Position
Momentum
20% ($1–$2) 52% ($4–$9) Stronger Trend EOLS
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.31β · 60% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 47.8 / 100 (HOLD) Higher Composite EOLS
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $325M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 66.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$8.8M ($124M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EOLS +14.52 pp
TLPH: -20.29% · EOLS: -5.77%
3M Horizon EOLS +10.63 pp
TLPH: -28.85% · EOLS: -18.22%
6M Horizon TLPH +6.15 pp
TLPH: +7.98% · EOLS: +1.83%
1Y Horizon EOLS +8.78 pp
TLPH: -18.01% · EOLS: -9.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs EOLS. Trailing 12-month operating profitability (TLPH -1474700.0% vs EOLS -5.4%) and valuation multiples (TLPH 1.0x vs EOLS 24.9x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
EOLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$325M
Gross Margin66.1%
Op. Margin-5.4%
ROE / Fwd P/E-18729.6% · 24.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EOLS CONSOLIDATION
100d in phase · OBV DISTRIBUTION
Current IV 46.4%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EOLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EOLS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $475.2M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 71.5% of Rev ($233M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs EOLS Key Questions & Quantitative Answers

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas EOLS carries 47.8/100 (HOLD) at $6.69 (24.9x Forward P/E, -5.4% operating margin). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EOLS leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with EOLS at +13.0% YoY revenue growth and +0.0% YoY earnings growth on $325M TTM revenue (66.1% gross margin, -5.4% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $325M for EOLS. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 71.5% of Rev ($233M) (0 disclosures) for EOLS.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas EOLS trades at 24.9x Forward P/E, 14.9x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-2.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus EOLS (-18729.6% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, EOLS carries 46.4% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.